AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that pancreatic ...
AGOURA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on RNA-based ...
Novel TROP2-targeted CAR T cells with high specificity and sustained efficacy for solid tumors in animal models. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...
Data supports further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma. SAN DIEGO, Calif., July 17, 2025 (GLOBE NEWSWIRE) - ...
AGOURA HILLS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic,” the “Company,” or “We”), a leader in RNA-based therapeutics, today announced the ...
AGOURA HILLS, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTLC). Oncotelic Therapeutics, a leader in RNA-based therapeutics, is pleased to announce that Vuong Trieu, Ph.D., ...
AGOURA HILLS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) and Interferon ...
Data support further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma (PDAC). AGOURA HILLS, Calif., July 17, 2025 (GLOBE ...
The study was co-authored by Dr. Sanjive Qazi, Dr. Michael Potts, Scott Myers, Dr. Stephen Richardson, and Dr. Vuong Trieu. PDAC remains one of the most lethal malignancies with limited treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results